Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
Castle Biosciences, Inc is a diagnostics & research business based in the US. Castle Biosciences shares (CSTL) are listed on the NASDAQ and all prices are listed in US Dollars. Castle Biosciences employs 133 staff and has a trailing 12-month revenue of around USD$62.5 million.
|Latest market close||USD$50.25|
|52-week range||USD$15.26 - USD$55.31|
|50-day moving average||USD$50.4256|
|200-day moving average||USD$40.6264|
|Wall St. target price||USD$55|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.14|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||15.25%|
|1 month (2020-11-06)||-2.80%|
|3 months (2020-09-04)||4.58%|
|6 months (2020-06-05)||33.32%|
|1 year (2019-12-05)||70.74%|
|2 years (2018-12-02)||N/A|
|3 years (2017-12-02)||N/A|
|5 years (2015-12-02)||N/A|
Valuing Castle Biosciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Castle Biosciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Castle Biosciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 512x. In other words, Castle Biosciences shares trade at around 512x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Castle Biosciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$5.9 million.
The EBITDA is a measure of a Castle Biosciences's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$62.5 million|
|Operating margin TTM||8.88%|
|Gross profit TTM||USD$44.6 million|
|Return on assets TTM||2.95%|
|Return on equity TTM||9.22%|
|Market capitalisation||USD$983.5 million|
TTM: trailing 12 months
There are currently 733,752 Castle Biosciences shares held short by investors – that's known as Castle Biosciences's "short interest". This figure is 40.3% up from 522,859 last month.
There are a few different ways that this level of interest in shorting Castle Biosciences shares can be evaluated.
Castle Biosciences's "short interest ratio" (SIR) is the quantity of Castle Biosciences shares currently shorted divided by the average quantity of Castle Biosciences shares traded daily (recently around 223024.92401216). Castle Biosciences's SIR currently stands at 3.29. In other words for every 100,000 Castle Biosciences shares traded daily on the market, roughly 3290 shares are currently held short.
However Castle Biosciences's short interest can also be evaluated against the total number of Castle Biosciences shares, or, against the total number of tradable Castle Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Castle Biosciences's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Castle Biosciences shares in existence, roughly 40 shares are currently held short) or 0.0642% of the tradable shares (for every 100,000 tradable Castle Biosciences shares, roughly 64 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Castle Biosciences.
Find out more about how you can short Castle Biosciences stock.
We're not expecting Castle Biosciences to pay a dividend over the next 12 months.
Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.